Market Place
Sourcing Support
Assertio Shares Rolvedon® Same-Day Dosing Study Results
13 Dec 2024 //
GLOBENEWSWIRE
Spectrum`s Biologic Rolvedon (Eflapegrastim) Receives Approval in the U.S.
16 Jun 2023 //
FDA
Spectrum Receives Permanent J-Code for ROLVEDON Injection from U.S. CMS
08 Feb 2023 //
BUSINESSWIRE
Spectrum Pharmaceuticals Provides Update on ROLVEDON Injection
31 Jan 2023 //
BUSINESSWIRE
Spectrum Pharma’s ROLVEDON Injection Added to NCCN Supportive Care Guidelines
06 Dec 2022 //
BUSINESSWIRE
Spectrum`s Biologic Rolvedon (Eflapegrastim) Receives Approval in the U.S.
09 Sep 2022 //
FDA
Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON Injection
09 Sep 2022 //
BUSINESSWIRE
Spectrum Pharmas Reports Second Quarter 2022 Financial Results
11 Aug 2022 //
BUSINESSWIRE
Spectrum Pharmaceuticals Announces Strategic Restructuring
05 Jan 2022 //
BUSINESSWIRE
Spectrum Pharmaceuticals Announces New Strategic Investment by Hanmi Pharma
04 Jan 2022 //
BUSINESSWIRE
FDA shoots down Spectrum`s neutropenia drug, citing manufacturing issues
07 Aug 2021 //
ENDPTS
FDA shoots down Spectrum`s neutropenia drug, citing manufacturing issues
06 Aug 2021 //
ENDPTS
Spectrum Announces Poster Presentation at Upcoming Miami Breast Cancer
26 Feb 2021 //
BUSINESSWIRE
FDA delays decision on Spectrum Pharma`s drug candidate due to travel curbs
28 Oct 2020 //
REUTERS
Spectrum Pharmaceuticals Presents Same Day Dosing Data for ROLONTIS®
22 Jun 2020 //
BUSINESSWIRE
Spectrum Presents Same Day Dosing Data for ROLONTIS® AACR
22 Jun 2020 //
BUSINESSWIRE
Spectrum to Present Preclinical ROLONTIS® (eflapegrastim) Same Day
16 Jun 2020 //
BIOSPACE
Spectrum Pharmaceuticals to Present Preclinical ROLONTIS® (eflapegrastim)
16 Jun 2020 //
BUSINESSWIRE
Spectrum Pharma nabs Five Prime, Gilead vet as clinical lead
04 Jun 2020 //
FIERCE BIOTECH
Spectrum`s Initiates Same Day Dosing Clinical Trial for ROLONTIS®
30 Apr 2020 //
BUSINESSWIRE
Spectrum Initiates Same Day Dosing Clinical Trial for ROLONTIS®
30 Apr 2020 //
BIOSPACE
Spectrum Pharma Announces Submission to the USFDA of Updated BLA for ROLONTIS®
25 Oct 2019 //
PR NEWSWIRE
Spectrum Pharmaceuticals sells marketed drugs to Aurobindo subsidiary for up to $300M
18 Jan 2019 //
MEDCITY NEWS
Spectrum Pharms Announces BLA Submission of ROLONTIS® (eflapegrastim) to FDA
28 Dec 2018 //
BUSINESSWIRE
Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS® (eflapegrastim)
29 Jun 2018 //
BUSINESSINSIDER
Spectrum to Host Conference Call Highlighting ROLONTIS® (eflapegrastim)
25 Jun 2018 //
BUSINESSWIRE
Spectrum Announces ROLONTIS™ (eflapegrastim) Met in the Phase 3
05 Feb 2018 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.